ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: FLARE

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Jeffrey Curtis, MD, MS, MPH  |  

ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

Tofacitinib Yields Rapid & Sustained Improvement in JIA

Reuters Staff  |  

NEW YORK (Reuters Health)—Tofacitinib significantly reduces the number of flares in children with polyarticular course juvenile idiopathic arthritis (JIA), according to the first phase-3 clinical trial to assess the efficacy of a Janus kinase (JAK) inhibitor in JIA. JIA is a heterogeneous group of chronic conditions with no known cause that develop before age 16…

Management of Adults with JIA: Uveitis, MAS & More

  |  

Mara L. Becker, MD, MSCE, discusses how important it is to effectively treat juvenile idiopathic arthritis at an early stage to improve long-term outcomes in adulthood.

Experts Discuss Blood Disorders Commonly Seen in Lupus Patients

  |  

ACR CONVERGENCE 2021—Hematologic abnormalities are common in systemic lupus erythematosus (SLE), whether due to SLE itself or something else. As rheumatology professionals, we are routinely challenged by the management of cytopenias in our SLE patients. At the ACR’s annual meeting in 2021, two hematologists shared expert advice regarding common hematologic manifestations of SLE. Michael B….

The Great Debate: Belimumab vs. Voclosporin in Lupus Nephritis

  |  

ACR Convergence 2021—The Great Debate at the meeting sparked a thoughtful discussion on the future of lupus nephritis treatment strategies, with experts saying clinicians should be open to new ways of approaching patient care. In the past year, approvals of the monoclonal antibody belimumab and the calcineurin inhibitor voclosporin for use in lupus nephritis (when…

Using the 2019 EULAR/ACR Classification Criteria to Predict Disease Severity in SLE

  |  

Predicting a patient’s disease course is difficult, especially in SLE. A recent study examined the link between a patient’s 2019 EULAR/ACR SLE Classification Criteria score at diagnosis to subsequent disease severity, finding a score of 20 or more may predict a more severe disease course.